Pharmacotherapy for obsessive-compulsive disorder: Real-world evidence from a 10-year retrospective data analysis

Sanghoon Oh; Sunwoo Cho; Sun Young Moon; Junhee Lee; Minah Kim; Tae Young Lee; Jun Soo Kwon

doi:10.1016/j.ajp.2023.103847

Pharmacotherapy for obsessive-compulsive disorder: Real-world evidence from a 10-year retrospective data analysis

Sanghoon Oh, Sunwoo Cho, Sun Young Moon, Junhee Lee, Minah Kim, Tae Young Lee, Jun Soo Kwon

Department of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

We investigated pharmacotherapy trends for obsessive-compulsive disorder (OCD) patients at a Korean tertiary hospital from 2008 to 2017. Out of 1894 patients, 82.9% received at least one psychotropic medication, with prescription rates increasing over time. The most frequently prescribed drug classes were selective serotonin reuptake inhibitors (SSRIs, 80.5%), anxiolytics (57.5%), antipsychotics (47.2%), other antidepressants (21.1%), and mood stabilizers (18.4%). Combination therapy was administered to 79.7% of medicated patients, with SSRIs, anxiolytics, and antipsychotics being the most common combination. Comorbidities significantly increased the prescription rates of all psychotropic classes (P < 0.001). Our study offers insights that may aid in bridging the gap between OCD treatment guidelines and real-world clinical practice.

Original language	English
Article number	103847
Journal	Asian Journal of Psychiatry
Volume	91
DOIs	https://doi.org/10.1016/j.ajp.2023.103847
State	Published - Jan 2024

Keywords

Comorbidity
Obsessive-compulsive disorder
Pharmacotherapy
Real-world prescription patterns
Treatment guidelines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ajp.2023.103847

Cite this

@article{c87193e660c34ad1843289b749246617,

title = "Pharmacotherapy for obsessive-compulsive disorder: Real-world evidence from a 10-year retrospective data analysis",

abstract = "We investigated pharmacotherapy trends for obsessive-compulsive disorder (OCD) patients at a Korean tertiary hospital from 2008 to 2017. Out of 1894 patients, 82.9% received at least one psychotropic medication, with prescription rates increasing over time. The most frequently prescribed drug classes were selective serotonin reuptake inhibitors (SSRIs, 80.5%), anxiolytics (57.5%), antipsychotics (47.2%), other antidepressants (21.1%), and mood stabilizers (18.4%). Combination therapy was administered to 79.7% of medicated patients, with SSRIs, anxiolytics, and antipsychotics being the most common combination. Comorbidities significantly increased the prescription rates of all psychotropic classes (P < 0.001). Our study offers insights that may aid in bridging the gap between OCD treatment guidelines and real-world clinical practice.",

keywords = "Comorbidity, Obsessive-compulsive disorder, Pharmacotherapy, Real-world prescription patterns, Treatment guidelines",

author = "Sanghoon Oh and Sunwoo Cho and Moon, {Sun Young} and Junhee Lee and Minah Kim and Lee, {Tae Young} and Kwon, {Jun Soo}",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2024",

month = jan,

doi = "10.1016/j.ajp.2023.103847",

language = "English",

volume = "91",

journal = "Asian Journal of Psychiatry",

issn = "1876-2018",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Pharmacotherapy for obsessive-compulsive disorder

T2 - Real-world evidence from a 10-year retrospective data analysis

AU - Oh, Sanghoon

AU - Cho, Sunwoo

AU - Moon, Sun Young

AU - Lee, Junhee

AU - Kim, Minah

AU - Lee, Tae Young

AU - Kwon, Jun Soo

PY - 2024/1

Y1 - 2024/1

N2 - We investigated pharmacotherapy trends for obsessive-compulsive disorder (OCD) patients at a Korean tertiary hospital from 2008 to 2017. Out of 1894 patients, 82.9% received at least one psychotropic medication, with prescription rates increasing over time. The most frequently prescribed drug classes were selective serotonin reuptake inhibitors (SSRIs, 80.5%), anxiolytics (57.5%), antipsychotics (47.2%), other antidepressants (21.1%), and mood stabilizers (18.4%). Combination therapy was administered to 79.7% of medicated patients, with SSRIs, anxiolytics, and antipsychotics being the most common combination. Comorbidities significantly increased the prescription rates of all psychotropic classes (P < 0.001). Our study offers insights that may aid in bridging the gap between OCD treatment guidelines and real-world clinical practice.

AB - We investigated pharmacotherapy trends for obsessive-compulsive disorder (OCD) patients at a Korean tertiary hospital from 2008 to 2017. Out of 1894 patients, 82.9% received at least one psychotropic medication, with prescription rates increasing over time. The most frequently prescribed drug classes were selective serotonin reuptake inhibitors (SSRIs, 80.5%), anxiolytics (57.5%), antipsychotics (47.2%), other antidepressants (21.1%), and mood stabilizers (18.4%). Combination therapy was administered to 79.7% of medicated patients, with SSRIs, anxiolytics, and antipsychotics being the most common combination. Comorbidities significantly increased the prescription rates of all psychotropic classes (P < 0.001). Our study offers insights that may aid in bridging the gap between OCD treatment guidelines and real-world clinical practice.

KW - Comorbidity

KW - Obsessive-compulsive disorder

KW - Pharmacotherapy

KW - Real-world prescription patterns

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=85179056308&partnerID=8YFLogxK

U2 - 10.1016/j.ajp.2023.103847

DO - 10.1016/j.ajp.2023.103847

M3 - Article

C2 - 38029602

AN - SCOPUS:85179056308

SN - 1876-2018

VL - 91

JO - Asian Journal of Psychiatry

JF - Asian Journal of Psychiatry

M1 - 103847

ER -

Pharmacotherapy for obsessive-compulsive disorder: Real-world evidence from a 10-year retrospective data analysis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this